{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T03:43:17Z","timestamp":1790480597110,"version":"4.1.0"},"reference-count":142,"publisher":"American Diabetes Association","issue":"7","license":[{"start":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T00:00:00Z","timestamp":1592524800000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/www.diabetesjournals.org\/content\/license"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,7,1]]},"abstract":"<jats:sec><jats:title>OBJECTIVE<\/jats:title><jats:p>To synthesize updated evidence on the cost-effectiveness (CE) of interventions to manage diabetes, its complications, and comorbidities.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESEARCH DESIGN AND METHODS<\/jats:title><jats:p>We conducted a systematic literature review of studies from high-income countries evaluating the CE of diabetes management interventions recommended by the American Diabetes Association (ADA) and published in English between June 2008 and July 2017. We also incorporated studies from a previous CE review from the period 1985\u20132008. We classified the interventions based on their strength of evidence (strong, supportive, or uncertain) and levels of CE: cost-saving (more health benefit at a lower cost), very cost-effective (\u2264$25,000 per life year gained [LYG] or quality-adjusted life year [QALY]), cost-effective ($25,001\u2013$50,000 per LYG or QALY), marginally cost-effective ($50,001\u2013$100,000 per LYG or QALY), or not cost-effective (&amp;gt;$100,000 per LYG or QALY). Costs were measured in 2017 U.S. dollars.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Seventy-three new studies met our inclusion criteria. These were combined with 49 studies from the previous review to yield 122 studies over the period 1985\u20132017. A large majority of the ADA-recommended interventions remain cost-effective. Specifically, we found strong evidence that the following ADA-recommended interventions are cost-saving or very cost-effective: In the cost-saving category are 1) ACE inhibitor (ACEI)\/angiotensin receptor blocker (ARB) therapy for intensive hypertension management compared with standard hypertension management, 2) ACEI\/ARB therapy to prevent chronic kidney disease and\/or end-stage renal disease in people with albuminuria compared with no ACEI\/ARB therapy, 3) comprehensive foot care and patient education to prevent and treat foot ulcers among those at moderate\/high risk of developing foot ulcers, 4) telemedicine for diabetic retinopathy screening compared with office screening, and 5) bariatric surgery compared with no surgery for individuals with type 2 diabetes (T2D) and obesity (BMI \u226530 kg\/m2). In the very cost-effective category are 1) intensive glycemic management (targeting A1C &amp;lt;7%) compared with conventional glycemic management (targeting an A1C level of 8\u201310%) for individuals with newly diagnosed T2D, 2) multicomponent interventions (involving behavior change\/education and pharmacological therapy targeting hyperglycemia, hypertension, dyslipidemia, microalbuminuria, nephropathy\/retinopathy, secondary prevention of cardiovascular disease with aspirin) compared with usual care, 3) statin therapy compared with no statin therapy for individuals with T2D and history of cardiovascular disease, 4) diabetes self-management education and support compared with usual care, 5) T2D screening every 3 years starting at age 45 years compared with no screening, 6) integrated, patient-centered care compared with usual care, 7) smoking cessation compared with no smoking cessation, 8) daily aspirin use as primary prevention for cardiovascular complications compared with usual care, 9) self-monitoring of blood glucose three times per day compared with once per day among those using insulin, 10) intensive glycemic management compared with conventional insulin therapy for T2D among adults aged \u226550 years, and 11) collaborative care for depression compared with usual care.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Complementing professional treatment recommendations, our systematic review provides an updated understanding of the potential value of interventions to manage diabetes and its complications and can assist clinicians and payers in prioritizing interventions and health care resources.<\/jats:p><\/jats:sec>","DOI":"10.2337\/dci20-0017","type":"journal-article","created":{"date-parts":[[2020,6,20]],"date-time":"2020-06-20T00:14:48Z","timestamp":1592612088000},"page":"1557-1592","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":157,"title":["Cost-effectiveness of Interventions to Manage Diabetes: Has the Evidence Changed Since 2008?"],"prefix":"10.2337","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6967-9088","authenticated-orcid":false,"given":"Karen R.","family":"Siegel","sequence":"first","affiliation":[{"name":"Division of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7266-2503","authenticated-orcid":false,"given":"Mohammed K.","family":"Ali","sequence":"additional","affiliation":[{"name":"Division of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, GA"},{"name":"Hubert Department of Global Health and Department of Family and Preventive Medicine, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3131-5948","authenticated-orcid":false,"given":"Xilin","family":"Zhou","sequence":"additional","affiliation":[{"name":"Division of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6070-661X","authenticated-orcid":false,"given":"Boon Peng","family":"Ng","sequence":"additional","affiliation":[{"name":"Division of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, GA"},{"name":"College of Nursing and Disability, Aging and Technology Cluster, University of Central Florida, Orlando, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn","family":"Jawanda","sequence":"additional","affiliation":[{"name":"Division of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista","family":"Proia","sequence":"additional","affiliation":[{"name":"Division of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanping","family":"Zhang","sequence":"additional","affiliation":[{"name":"Division of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2381-6822","authenticated-orcid":false,"given":"Edward W.","family":"Gregg","sequence":"additional","affiliation":[{"name":"Division of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann L.","family":"Albright","sequence":"additional","affiliation":[{"name":"Division of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8429-6301","authenticated-orcid":false,"given":"Ping","family":"Zhang","sequence":"additional","affiliation":[{"name":"Division of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2020,6,11]]},"reference":[{"key":"2022031300300435100_B1","volume-title":"National Diabetes Statistics Report, 2017","author":"Centers for Disease Control and Prevention","year":"2017"},{"key":"2022031300300435100_B2","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2337\/dci18-0007","article-title":"Economic costs of diabetes in the U.S. in 2017","volume":"41","author":"American Diabetes Association","year":"2018","journal-title":"Diabetes Care"},{"key":"2022031300300435100_B3","doi-asserted-by":"crossref","first-page":"10","DOI":"10.2337\/cd20-as01","article-title":"Standards of Medical Care in Diabetes\u20142020 abridged for primary care providers","volume":"38","author":"American Diabetes Association","year":"2020","journal-title":"Clin Diabetes"},{"key":"2022031300300435100_B4","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.2337\/dc10-0843","article-title":"Cost-effectiveness of interventions to prevent and control diabetes mellitus: a systematic review","volume":"33","author":"Li","year":"2010","journal-title":"Diabetes Care"},{"key":"2022031300300435100_B5","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.2337\/dc08-S012","article-title":"Standards of medical care in diabetes\u20142008","volume":"31","author":"American Diabetes Association","year":"2008","journal-title":"Diabetes Care"},{"key":"2022031300300435100_B6","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.2337\/dc18-su09","article-title":"Updates to the Standards of Medical Care in Diabetes\u20142018","volume":"41","author":"Association American Diabetes","year":"2018","journal-title":"Diabetes Care"},{"key":"2022031300300435100_B7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2337\/cd18-0105","article-title":"Standards of Medical Care in Diabetes\u20142019 abridged for primary care providers","volume":"37","author":"American Diabetes Association","year":"2019","journal-title":"Clin Diabetes"},{"key":"2022031300300435100_B8","article-title":"Cochrane Reviewers\u2019 Handbook 4.2.0","author":"Clarke","year":"2003","journal-title":"The Cochrane Libr"},{"key":"2022031300300435100_B9","volume-title":"World Bank Country and Lending Groups","author":"The World Bank","year":"2017"},{"key":"2022031300300435100_B10","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1136\/bmj.313.7052.275","article-title":"Guidelines for authors and peer reviewers of economic submissions to the BMJ","volume":"313","author":"Drummond","year":"1996","journal-title":"BMJ"},{"key":"2022031300300435100_B11","unstructured":"U.S. Bureau of Labor Statistics . Consumer Price Index, 2017. Available from https:\/\/www.bls.gov\/cpi\/. Accessed 20 March 2018"},{"key":"2022031300300435100_B12","unstructured":"The Federal Reserve . Foreign exchange rates (annual). Available from http:\/\/www.federalreserve.gov\/releases\/g5a\/. Accessed 28 August 2017"},{"key":"2022031300300435100_B13","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.2337\/dc19-Sint01","article-title":"Introduction: Standards of Medical Care in Diabetes\u20142019","volume":"42","author":"American Diabetes Association","year":"2019","journal-title":"Diabetes Care"},{"key":"2022031300300435100_B14","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.2337\/dc19-Srev01","article-title":"Summary of revisions: Standards of Medical Care in Diabetes\u20142019","volume":"42","author":"American Diabetes Association","year":"2019","journal-title":"Diabetes Care"},{"key":"2022031300300435100_B15","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/s11606-018-4705-2","article-title":"The importance of addressing depression and diabetes distress in adults with type 2 diabetes","volume":"34","author":"Owens-Gary","year":"2019","journal-title":"J Gen Intern Med"},{"key":"2022031300300435100_B16","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1056\/NEJMc1306652","article-title":"Achievement of goals in U.S. diabetes care, 1999-2010","volume":"369","author":"Ali","year":"2013","journal-title":"N Engl J Med"},{"key":"2022031300300435100_B17","doi-asserted-by":"crossref","first-page":"681","DOI":"10.7326\/M14-0019","article-title":"A cascade of care for diabetes in the United States: visualizing the gaps","volume":"161","author":"Ali","year":"2014","journal-title":"Ann Intern Med"},{"key":"2022031300300435100_B18","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa1804988","article-title":"Effects of aspirin for primary prevention in persons with diabetes mellitus","volume":"379","author":"Bowman","year":"2018","journal-title":"N Engl J Med"},{"key":"2022031300300435100_B19","doi-asserted-by":"crossref","first-page":"416","DOI":"10.2337\/dc17-1144","article-title":"The legacy effect in type 2 diabetes: impact of early glycemic control on future complications (the Diabetes & Aging Study)","volume":"42","author":"Laiteerapong","year":"2019","journal-title":"Diabetes Care"},{"key":"2022031300300435100_B20","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1001\/jama.2018.6798","article-title":"Glycemic control in nonpregnant adults with type 2 diabetes","volume":"319","author":"Tung","year":"2018","journal-title":"JAMA"},{"key":"2022031300300435100_B21","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1001\/jama.280.20.1757","article-title":"The cost-effectiveness of screening for type 2 diabetes","volume":"280","author":"CDC Diabetes Cost-Effectiveness Study Group","year":"1998","journal-title":"JAMA"},{"key":"2022031300300435100_B22","doi-asserted-by":"crossref","first-page":"689","DOI":"10.7326\/0003-4819-140-9-200405040-00008","article-title":"Screening for type 2 diabetes mellitus: a cost-effectiveness analysis","volume":"140","author":"Hoerger","year":"2004","journal-title":"Ann Intern Med"},{"key":"2022031300300435100_B23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta19330","article-title":"The cost-effectiveness of testing strategies for type 2 diabetes: a modelling study","volume":"19","author":"Gillett","year":"2015","journal-title":"Health Technol Assess"},{"key":"2022031300300435100_B24","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/S0140-6736(09)62162-0","article-title":"Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis","volume":"375","author":"Kahn","year":"2010","journal-title":"Lancet"},{"key":"2022031300300435100_B25","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.2337\/diacare.28.6.1482","article-title":"Screening for gestational diabetes mellitus: a decision and cost-effectiveness analysis of four screening strategies","volume":"28","author":"Nicholson","year":"2005","journal-title":"Diabetes Care"},{"key":"2022031300300435100_B26","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2337\/dc11-1643","article-title":"Screening for gestational diabetes mellitus: are the criteria proposed by the International Association of the Diabetes and Pregnancy Study Groups cost-effective?","volume":"35","author":"Werner","year":"2012","journal-title":"Diabetes Care"},{"key":"2022031300300435100_B27","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/1010539515612908","article-title":"Incremental cost-effectiveness analysis of gestational diabetes mellitus screening strategies in Singapore","volume":"28","author":"Chen","year":"2016","journal-title":"Asia Pac J Public Health"},{"key":"2022031300300435100_B28","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1007\/s00125-015-3824-0","article-title":"The cost-effectiveness of screening for gestational diabetes mellitus in primary and secondary care in the Republic of Ireland","volume":"59","author":"Danyliv","year":"2016","journal-title":"Diabetologia"},{"key":"2022031300300435100_B29","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1001\/jama.1996.03540170053032","article-title":"Lifetime benefits and costs of intensive therapy as practiced in the Diabetes Control and Complications Trial","volume":"276","author":"The Diabetes Control and Complications Trial Research Group","year":"1996","journal-title":"JAMA"},{"key":"2022031300300435100_B30","doi-asserted-by":"crossref","first-page":"735","DOI":"10.2337\/diacare.20.5.735","article-title":"Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia","volume":"20","author":"Eastman","year":"1997","journal-title":"Diabetes Care"},{"key":"2022031300300435100_B31","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1136\/bmj.320.7246.1373","article-title":"Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41)","volume":"320","author":"Gray","year":"2000","journal-title":"BMJ"},{"key":"2022031300300435100_B32","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s001250050003","article-title":"The cost-effectiveness of different management strategies for type I diabetes: a Swiss perspective","volume":"43","author":"Palmer","year":"2000","journal-title":"Diabetologia"},{"key":"2022031300300435100_B33","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0168-8227(00)00122-4","article-title":"Cost-effectiveness of intensive insulin therapy for type 2 diabetes: a 10-year follow-up of the Kumamoto study","volume":"48","author":"Wake","year":"2000","journal-title":"Diabetes Res Clin Pract"},{"key":"2022031300300435100_B34","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s001250051617","article-title":"Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51)","volume":"44","author":"Clarke","year":"2001","journal-title":"Diabetologia"},{"key":"2022031300300435100_B35","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1001\/jama.287.19.2542","article-title":"Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes","volume":"287","author":"CDC Diabetes Cost-effectiveness Group","year":"2002","journal-title":"JAMA"},{"key":"2022031300300435100_B36","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1046\/j.1464-5491.2003.00991.x","article-title":"The cost-effectiveness of continuous subcutaneous insulin infusion compared with multiple daily injections for the management of diabetes","volume":"20","author":"Scuffham","year":"2003","journal-title":"Diabet Med"},{"key":"2022031300300435100_B37","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1464-5491.2005.01576.x","article-title":"Health-economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of type 1 diabetes in the UK","volume":"22","author":"Roze","year":"2005","journal-title":"Diabet Med"},{"key":"2022031300300435100_B38","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1007\/s00125-005-1717-3","article-title":"Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72)","volume":"48","author":"Clarke","year":"2005","journal-title":"Diabetologia"},{"key":"2022031300300435100_B39","doi-asserted-by":"crossref","first-page":"251","DOI":"10.7326\/0003-4819-143-4-200508160-00006","article-title":"Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes","volume":"143","author":"Eddy","year":"2005","journal-title":"Ann Intern Med"},{"key":"2022031300300435100_B40","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1503\/cmaj.081180","article-title":"Cost-effectiveness of insulin analogues for diabetes mellitus","volume":"180","author":"Cameron","year":"2009","journal-title":"CMAJ"},{"key":"2022031300300435100_B41","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/j.1524-4733.2009.00668.x","article-title":"Cost-effectiveness of screening and optimal management for diabetes, hypertension, and chronic kidney disease: a modeled analysis","volume":"13","author":"Howard","year":"2010","journal-title":"Value Health"},{"key":"2022031300300435100_B42","doi-asserted-by":"crossref","first-page":"E1213","DOI":"10.1503\/cmaj.110178","article-title":"Cost-effectiveness of second-line antihyperglycemic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin","volume":"183","author":"Klarenbach","year":"2011","journal-title":"CMAJ"},{"key":"2022031300300435100_B43","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/dom.12867","article-title":"Managing glycaemia in older people with type 2 diabetes: a retrospective, primary care-based cohort study, with economic assessment of patient outcomes","volume":"19","author":"Gordon","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"2022031300300435100_B44","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1136\/bmj.39526.674873.BE","article-title":"Cost effectiveness of self monitoring of blood glucose in patients with non-insulin treated type 2 diabetes: economic evaluation of data from the DiGEM trial","volume":"336","author":"Simon","year":"2008","journal-title":"BMJ"},{"key":"2022031300300435100_B45","first-page":"131","article-title":"Self-monitoring of blood glucose in type 2 diabetes: cost-effectiveness in the united states","volume":"14","author":"Tunis","year":"2008","journal-title":"Am J Manag Care"},{"key":"2022031300300435100_B46","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1503\/cmaj.090765","article-title":"Cost-effectiveness of self-monitoring of blood glucose in patients with type 2 diabetes mellitus managed without insulin","volume":"182","author":"Cameron","year":"2010","journal-title":"CMAJ"},{"key":"2022031300300435100_B47","first-page":"w13103","article-title":"Evaluating the cost-effectiveness of self-monitoring of blood glucose in type 2 diabetes patients on oral anti-diabetic agents","volume":"140","author":"Pollock","year":"2010","journal-title":"Swiss Med Wkly"},{"key":"2022031300300435100_B48","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1185\/03007990903400071","article-title":"Self-monitoring of blood glucose (SMBG) for type 2 diabetes patients treated with oral anti-diabetes drugs and with a recent history of monitoring: cost-effectiveness in the US","volume":"26","author":"Tunis","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"2022031300300435100_B49","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1185\/03007990903429765","article-title":"Self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes on oral anti-diabetes drugs: cost-effectiveness in France, Germany, Italy, and Spain","volume":"26","author":"Tunis","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"2022031300300435100_B50","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2165\/11594270-000000000-00000","article-title":"Cost effectiveness of self-monitoring of blood glucose (SMBG) for patients with type 2 diabetes and not on insulin: impact of modelling assumptions on recent Canadian findings","volume":"9","author":"Tunis","year":"2011","journal-title":"Appl Health Econ Health Policy"},{"key":"2022031300300435100_B51","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1177\/1932296815599551","article-title":"Economic value of improved accuracy for self-monitoring of blood glucose devices for type 1 diabetes in Canada","volume":"10","author":"McQueen","year":"2015","journal-title":"J Diabetes Sci Technol"},{"key":"2022031300300435100_B52","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1136\/bmj.317.7160.720","article-title":"Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40","volume":"317","author":"UK Prospective Diabetes Study Group","year":"1998","journal-title":"BMJ"},{"key":"2022031300300435100_B53","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1001\/archinte.160.9.1277","article-title":"Cost-effectiveness of the lower treatment goal (of JNC VI) for diabetic hypertensive patients. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure","volume":"160","author":"Elliott","year":"2000","journal-title":"Arch Intern Med"},{"key":"2022031300300435100_B54","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/j.1751-7176.2009.00082.x","article-title":"Cost effectiveness analysis of a hypertension management program in patients with type 2 diabetes","volume":"11","author":"Ly","year":"2009","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2022031300300435100_B55","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.2337\/diacare.22.11.1771","article-title":"Effect of simvastatin treatment on cardiovascular resource utilization in impaired fasting glucose and diabetes. Findings from the Scandinavian Simvastatin Survival Study","volume":"22","author":"Herman","year":"1999","journal-title":"Diabetes Care"},{"key":"2022031300300435100_B56","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s001250051441","article-title":"The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial","volume":"42","author":"J\u00f6nsson","year":"1999","journal-title":"Diabetologia"},{"key":"2022031300300435100_B57","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1161\/01.CIR.102.7.722","article-title":"Cost-effectiveness of treating hyperlipidemia in the presence of diabetes: who should be treated?","volume":"102","author":"Grover","year":"2000","journal-title":"Circulation"},{"key":"2022031300300435100_B58","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00125-006-0561-4","article-title":"Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS)","volume":"50","author":"Raikou","year":"2007","journal-title":"Diabetologia"},{"key":"2022031300300435100_B59","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.clinthera.2009.04.015","article-title":"Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia","volume":"31","author":"Sorensen","year":"2009","journal-title":"Clin Ther"},{"key":"2022031300300435100_B60","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jval.2013.12.010","article-title":"Cost-effectiveness of statins for primary prevention in patients newly diagnosed with type 2 diabetes in the Netherlands","volume":"17","author":"de Vries","year":"2014","journal-title":"Value Health"},{"key":"2022031300300435100_B61","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1177\/027298902237704","article-title":"Optimal allocation of resources across four interventions for type 2 diabetes","volume":"22","author":"Earnshaw","year":"2002","journal-title":"Med Decis Making"},{"key":"2022031300300435100_B62","first-page":"303","article-title":"Economic and clinical impact of alternative disease management strategies for secondary prevention in type 2 diabetes in the Swiss setting","volume":"131","author":"Gozzoli","year":"2001","journal-title":"Swiss Med Wkly"},{"key":"2022031300300435100_B63","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1464-5491.2004.01183.x","article-title":"Cost-effectiveness of flexible intensive insulin management to enable dietary freedom in people with type 1 diabetes in the UK","volume":"21","author":"Shearer","year":"2004","journal-title":"Diabet Med"},{"key":"2022031300300435100_B64","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1177\/0145721709340931","article-title":"Cost-effectiveness of diabetes self-management programs in community primary care settings","volume":"35","author":"Brownson","year":"2009","journal-title":"Diabetes Educ"},{"key":"2022031300300435100_B65","doi-asserted-by":"crossref","first-page":"c4093","DOI":"10.1136\/bmj.c4093","article-title":"Delivering the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cost effectiveness analysis","volume":"341","author":"Gillett","year":"2010","journal-title":"BMJ"},{"key":"2022031300300435100_B66","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/1745-6215-15-227","article-title":"Cost effectiveness of group follow-up after structured education for type 1 diabetes: a cluster randomised controlled trial","volume":"15","author":"Gillespie","year":"2014","journal-title":"Trials"},{"key":"2022031300300435100_B67","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1111\/dme.12270","article-title":"The cost-effectiveness of the Dose Adjustment for Normal Eating (DAFNE) structured education programme: an update using the Sheffield Type 1 Diabetes Policy Model","volume":"30","author":"Kruger","year":"2013","journal-title":"Diabet Med"},{"key":"2022031300300435100_B68","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.diabres.2013.12.032","article-title":"A cost-effectiveness analysis of a telephone-linked care intervention for individuals with type 2 diabetes","volume":"104","author":"Gordon","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"key":"2022031300300435100_B69","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.amepre.2014.08.016","article-title":"The Community Diabetes Education (CoDE) program: cost-effectiveness and health outcomes","volume":"47","author":"Prezio","year":"2014","journal-title":"Am J Prev Med"},{"key":"2022031300300435100_B70","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.puhe.2014.05.002","article-title":"Cost-effectiveness of community health workers in controlling diabetes epidemic on the U.S.-Mexico border","volume":"128","author":"Ryabov","year":"2014","journal-title":"Public Health"},{"key":"2022031300300435100_B71","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1186\/s12913-016-1645-6","article-title":"The cost-effectiveness of hospital-based telephone coaching for people with type 2 diabetes: a 10 year modelling analysis","volume":"16","author":"Varney","year":"2016","journal-title":"BMC Health Serv Res"},{"key":"2022031300300435100_B72","doi-asserted-by":"crossref","first-page":"e0163997","DOI":"10.1371\/journal.pone.0163997","article-title":"Delivering diabetes education through nurse-led telecoaching. cost-effectiveness analysis","volume":"11","author":"Odnoletkova","year":"2016","journal-title":"PLoS One"},{"key":"2022031300300435100_B73","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.2337\/dc09-1888","article-title":"Cost-effectiveness of aspirin use among persons with newly diagnosed type 2 diabetes","volume":"33","author":"Li","year":"2010","journal-title":"Diabetes Care"},{"key":"2022031300300435100_B74","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12933-016-0363-z","article-title":"Cost-effectiveness of screening strategies to detect heart failure in patients with type 2 diabetes","volume":"15","author":"van Giessen","year":"2016","journal-title":"Cardiovasc Diabetol"},{"key":"2022031300300435100_B75","doi-asserted-by":"crossref","first-page":"909","DOI":"10.2337\/diacare.17.8.909","article-title":"Preventive eye care in people with diabetes is cost-saving to the federal government. Implications for health-care reform","volume":"17","author":"Javitt","year":"1994","journal-title":"Diabetes Care"},{"key":"2022031300300435100_B76","doi-asserted-by":"crossref","first-page":"164","DOI":"10.7326\/0003-4819-124-1_Part_2-199601011-00017","article-title":"Cost-effectiveness of detecting and treating diabetic retinopathy","volume":"124","author":"Javitt","year":"1996","journal-title":"Ann Intern Med"},{"key":"2022031300300435100_B77","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1001\/jama.283.7.889","article-title":"Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus","volume":"283","author":"Vijan","year":"2000","journal-title":"JAMA"},{"key":"2022031300300435100_B78","first-page":"160","article-title":"Screening for diabetic retinopathy in James Bay, Ontario: a cost-effectiveness analysis","volume":"168","author":"Maberley","year":"2003","journal-title":"CMAJ"},{"key":"2022031300300435100_B79","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1016\/j.ophtha.2013.06.029","article-title":"Evaluation of telemedicine for screening of diabetic retinopathy in the Veterans Health Administration","volume":"120","author":"Kirkizlar","year":"2013","journal-title":"Ophthalmology"},{"key":"2022031300300435100_B80","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1016\/j.ophtha.2015.06.050","article-title":"Cost-effectiveness of screening for intermediate age-related macular degeneration during diabetic retinopathy screening","volume":"122","author":"Chan","year":"2015","journal-title":"Ophthalmology"},{"key":"2022031300300435100_B81","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3109\/09286586.2014.988876","article-title":"Cost-utility analysis of screening for diabetic retinopathy in Japan: a probabilistic Markov modeling study","volume":"22","author":"Kawasaki","year":"2015","journal-title":"Ophthalmic Epidemiol"},{"key":"2022031300300435100_B82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta19740","article-title":"Development of a cost-effectiveness model for optimisation of the screening interval in diabetic retinopathy screening","volume":"19","author":"Scanlon","year":"2015","journal-title":"Health Technol Assess"},{"key":"2022031300300435100_B83","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1136\/jmedgenet-2017-104670","article-title":"Incremental cost-effectiveness of algorithm-driven genetic testing versus no testing for maturity onset diabetes of the young (MODY) in Singapore","volume":"54","author":"Nguyen","year":"2017","journal-title":"J Med Genet"},{"key":"2022031300300435100_B84","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/dme.13129","article-title":"Modelling the cost-effectiveness of adopting risk-stratified approaches to extended screening intervals in the national diabetic retinopathy screening programme in Scotland","volume":"33","author":"Scotland","year":"2016","journal-title":"Diabet Med"},{"key":"2022031300300435100_B85","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.jval.2017.04.015","article-title":"Cost-utility analysis of extending public health insurance coverage to include diabetic retinopathy screening by optometrists","volume":"20","author":"van Katwyk","year":"2017","journal-title":"Value Health"},{"key":"2022031300300435100_B86","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1007\/s001250100013","article-title":"Prevention of diabetes-related foot ulcers and amputations: a cost-utility analysis based on Markov model simulations","volume":"44","author":"Ragnarson Tennvall","year":"2001","journal-title":"Diabetologia"},{"key":"2022031300300435100_B87","doi-asserted-by":"crossref","first-page":"901","DOI":"10.2337\/diacare.27.4.901","article-title":"Cost-effectiveness of prevention and treatment of the diabetic foot: a Markov analysis","volume":"27","author":"Ortegon","year":"2004","journal-title":"Diabetes Care"},{"key":"2022031300300435100_B88","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1136\/bmj.306.6894.1722","article-title":"Is screening and intervention for microalbuminuria worthwhile in patients with insulin dependent diabetes?","volume":"306","author":"Borch-Johnsen","year":"1993","journal-title":"BMJ"},{"key":"2022031300300435100_B89","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1136\/bmj.311.7020.1595","article-title":"Screening to prevent renal failure in insulin dependent diabetic patients: an economic evaluation","volume":"311","author":"Kiberd","year":"1995","journal-title":"BMJ"},{"key":"2022031300300435100_B90","doi-asserted-by":"crossref","first-page":"660","DOI":"10.7326\/0003-4819-131-9-199911020-00005","article-title":"The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors","volume":"131","author":"Golan","year":"1999","journal-title":"Ann Intern Med"},{"key":"2022031300300435100_B91","first-page":"195","article-title":"To pay or not to pay? A decision and cost-utility analysis of angiotensin-converting-enzyme inhibitor therapy for diabetic nephropathy","volume":"162","author":"Clark","year":"2000","journal-title":"CMAJ"},{"key":"2022031300300435100_B92","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1093\/ndt\/gfg232","article-title":"An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings","volume":"18","author":"Palmer","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"2022031300300435100_B93","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1262-3636(07)70004-6","article-title":"An economic evaluation of Losartan therapy in type 2 diabetic patients with nephropathy: an analysis of the RENAAL study adapted to France","volume":"29","author":"Souchet","year":"2003","journal-title":"Diabetes Metab"},{"key":"2022031300300435100_B94","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.2165\/00019053-200422150-00005","article-title":"Cost effectiveness of ACE inhibitor treatment for patients with type 1 diabetes mellitus","volume":"22","author":"Dong","year":"2004","journal-title":"Pharmacoeconomics"},{"key":"2022031300300435100_B95","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/sj.jhh.1001729","article-title":"An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting","volume":"18","author":"Palmer","year":"2004","journal-title":"J Hum Hypertens"},{"key":"2022031300300435100_B96","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.2337\/diacare.27.8.1897","article-title":"Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease","volume":"27","author":"Palmer","year":"2004","journal-title":"Diabetes Care"},{"key":"2022031300300435100_B97","first-page":"440","article-title":"The cost-effectiveness of losartan in type 2 diabetics with nephropathy in Switzerland\u2014an analysis of the RENAAL study","volume":"134","author":"Szucs","year":"2004","journal-title":"Swiss Med Wkly"},{"key":"2022031300300435100_B98","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1111\/j.1523-1755.2005.09312.x","article-title":"Irbesartan is projected to be cost and life saving in a Spanish setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria","volume":"67","author":"Palmer","year":"2005","journal-title":"Kidney Int Suppl"},{"key":"2022031300300435100_B99","doi-asserted-by":"crossref","first-page":"89","DOI":"10.7326\/0003-4819-143-2-200507190-00007","article-title":"Cost-effectiveness of full medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes","volume":"143","author":"Rosen","year":"2005","journal-title":"Ann Intern Med"},{"key":"2022031300300435100_B100","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/j.clinthera.2007.07.029","article-title":"Cost-effectiveness of irbesartan 300 mg given early versus late in patients with hypertension and a history of type 2 diabetes and renal disease: a Canadian perspective","volume":"29","author":"Coyle","year":"2007","journal-title":"Clin Ther"},{"key":"2022031300300435100_B101","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s10198-006-0033-2","article-title":"Health economic implications of irbesartan treatment versus standard blood pressure control in patients with type 2 diabetes, hypertension and renal disease: a Hungarian analysis","volume":"8","author":"Palmer","year":"2007","journal-title":"Eur J Health Econ"},{"key":"2022031300300435100_B102","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1111\/j.1742-1241.2007.01343.x","article-title":"Irbesartan treatment of patients with type 2 diabetes, hypertension and renal disease: a UK health economics analysis","volume":"61","author":"Palmer","year":"2007","journal-title":"Int J Clin Pract"},{"key":"2022031300300435100_B103","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.2337\/dc07-2452","article-title":"Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 study","volume":"31","author":"Gaede","year":"2008","journal-title":"Diabetes Care"},{"key":"2022031300300435100_B104","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1353\/hpu.0.0258","article-title":"Cost-effectiveness of treating hypertension, hyperglycemia, and hyperlipidemia in African Americans and the general population with type 2 diabetes","volume":"21","author":"Tasosa","year":"2010","journal-title":"J Health Care Poor Underserved"},{"key":"2022031300300435100_B105","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/dme.12366","article-title":"Improving quality of care in people with type 2 diabetes through the Associazione Medici Diabetologi-annals initiative: a long-term cost-effectiveness analysis","volume":"31","author":"Giorda","year":"2014","journal-title":"Diabet Med"},{"key":"2022031300300435100_B106","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.jval.2017.05.018","article-title":"Incremental costs and cost effectiveness of intensive treatment in individuals with type 2 diabetes detected by screening in the ADDITION-UK trial: an update with empirical trial-based cost data","volume":"20","author":"Laxy","year":"2017","journal-title":"Value Health"},{"key":"2022031300300435100_B107","doi-asserted-by":"crossref","first-page":"40","DOI":"10.2337\/diacare.28.1.40","article-title":"Specialist nurse-led clinics to improve control of hypertension and hyperlipidemia in diabetes: economic analysis of the SPLINT trial","volume":"28","author":"Mason","year":"2005","journal-title":"Diabetes Care"},{"key":"2022031300300435100_B108","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1111\/j.1475-6773.2007.00701.x","article-title":"Cost-effectiveness of diabetes case management for low-income populations","volume":"42","author":"Gilmer","year":"2007","journal-title":"Health Serv Res"},{"key":"2022031300300435100_B109","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/1472-6963-8-205","article-title":"A cost effectiveness study of integrated care in health services delivery: a diabetes program in Australia","volume":"8","author":"McRae","year":"2008","journal-title":"BMC Health Serv Res"},{"key":"2022031300300435100_B110","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1097\/MLR.0b013e3181eb318f","article-title":"Cost-effectiveness of a quality improvement collaborative focusing on patients with diabetes","volume":"48","author":"Schouten","year":"2010","journal-title":"Med Care"},{"key":"2022031300300435100_B111","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1177\/193229681100500305","article-title":"Cost-effectiveness of implementing the chronic care model for diabetes care in a military population","volume":"5","author":"Kuo","year":"2011","journal-title":"J Diabetes Sci Technol"},{"key":"2022031300300435100_B112","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s40258-013-0062-9","article-title":"A model-based economic evaluation of improved primary care management of patients with type 2 diabetes in Australia","volume":"11","author":"Haji Ali Afzali","year":"2013","journal-title":"Appl Health Econ Health Policy"},{"key":"2022031300300435100_B113","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.2337\/dc12-1865","article-title":"Stratified patient-centered care in type 2 diabetes: a cluster-randomized, controlled clinical trial of effectiveness and cost-effectiveness","volume":"36","author":"Slingerland","year":"2013","journal-title":"Diabetes Care"},{"key":"2022031300300435100_B114","doi-asserted-by":"crossref","first-page":"102","DOI":"10.18553\/jmcp.2013.19.2.102","article-title":"A Markov model of the cost-effectiveness of pharmacist care for diabetes in prevention of cardiovascular diseases: evidence from Kaiser Permanente Northern California","volume":"19","author":"Yu","year":"2013","journal-title":"J Manag Care Pharm"},{"key":"2022031300300435100_B115","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1478-7547-12-17","article-title":"Changes in costs and effects after the implementation of disease management programs in the Netherlands: variability and determinants","volume":"12","author":"Tsiachristas","year":"2014","journal-title":"Cost Eff Resour Alloc"},{"key":"2022031300300435100_B116","doi-asserted-by":"crossref","first-page":"e93964","DOI":"10.1371\/journal.pone.0093964","article-title":"Evaluation of the clinical and cost effectiveness of intermediate care clinics for diabetes (ICCD): a multicentre cluster randomised controlled trial","volume":"9","author":"Wilson","year":"2014","journal-title":"PLoS One"},{"key":"2022031300300435100_B117","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/dme.12711","article-title":"Cost-effectiveness of intensive multifactorial treatment compared with routine care for individuals with screen-detected type 2 diabetes: analysis of the ADDITION-UK cluster-randomized controlled trial","volume":"32","author":"Tao","year":"2015","journal-title":"Diabet Med"},{"key":"2022031300300435100_B118","first-page":"318","article-title":"Estimated cost-effectiveness, cost benefit, and risk reduction associated with an endocrinologist-pharmacist Diabetes Intense Medical Management \u201cTune-Up\u201d clinic","volume":"23","author":"Hirsch","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"key":"2022031300300435100_B119","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2147\/PPA.S12121","article-title":"Modeling the economic impact of medication adherence in type 2 diabetes: a theoretical approach","volume":"4","author":"Cobden","year":"2010","journal-title":"Patient Prefer Adherence"},{"key":"2022031300300435100_B120","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2337\/dc09-1232","article-title":"Cost-effectiveness of the diabetes care protocol, a multifaceted computerized decision support diabetes management intervention that reduces cardiovascular risk","volume":"33","author":"Cleveringa","year":"2010","journal-title":"Diabetes Care"},{"key":"2022031300300435100_B121","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1136\/amiajnl-2011-000371","article-title":"Cost-effectiveness of a shared computerized decision support system for diabetes linked to electronic medical records","volume":"19","author":"O\u2019Reilly","year":"2012","journal-title":"J Am Med Inform Assoc"},{"key":"2022031300300435100_B122","first-page":"e147","article-title":"Cost-effectiveness of medication therapy management in Part D diabetic enrollees","volume":"6","author":"Olvey","year":"2014","journal-title":"Am J Pharm Benefits"},{"key":"2022031300300435100_B123","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1017\/S0266462311000663","article-title":"Cost effectiveness of peer support for type 2 diabetes","volume":"28","author":"Gillespie","year":"2012","journal-title":"Int J Technol Assess Health Care"},{"key":"2022031300300435100_B124","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1161\/CIRCULATIONAHA.109.912709","article-title":"Economic outcomes of treatment strategies for type 2 diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial","volume":"120","author":"Hlatky","year":"2009","journal-title":"Circulation"},{"key":"2022031300300435100_B125","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/00055735-200106000-00016","article-title":"The cost-effectiveness of early vitrectomy for the treatment of vitreous hemorrhage in diabetic retinopathy","volume":"12","author":"Sharma","year":"2001","journal-title":"Curr Opin Ophthalmol"},{"key":"2022031300300435100_B126","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1136\/bjophthalmol-2011-300726","article-title":"Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial","volume":"96","author":"Mitchell","year":"2012","journal-title":"Br J Ophthalmol"},{"key":"2022031300300435100_B127","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1001\/jamaophthalmol.2017.0837","article-title":"Cost-effectiveness of intravitreous ranibizumab compared with panretinal photocoagulation for proliferative diabetic retinopathy: secondary analysis from a Diabetic Retinopathy Clinical Research Network randomized clinical trial","volume":"135","author":"Hutton","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"2022031300300435100_B128","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/j.1365-2753.2006.00770.x","article-title":"A model to analyse costs and benefit of intensified diabetic foot care in Austria","volume":"13","author":"Habacher","year":"2007","journal-title":"J Eval Clin Pract"},{"key":"2022031300300435100_B129","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.2165\/0019053-200826120-00007","article-title":"A cost-utility comparison of four first-line medications in painful diabetic neuropathy","volume":"26","author":"O\u2019Connor","year":"2008","journal-title":"Pharmacoeconomics"},{"key":"2022031300300435100_B130","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/iwj.12653","article-title":"A cost-effectiveness analysis of optimal care for diabetic foot ulcers in Australia","volume":"14","author":"Cheng","year":"2017","journal-title":"Int Wound J"},{"key":"2022031300300435100_B131","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1007\/s11695-009-9946-z","article-title":"Cost-effectiveness and budget impact of obesity surgery in patients with type 2 diabetes in three European countries(II)","volume":"19","author":"Anselmino","year":"2009","journal-title":"Obes Surg"},{"key":"2022031300300435100_B132","first-page":"607","article-title":"Cost-effectiveness of Roux-en-Y gastric bypass in type 2 diabetes patients","volume":"15","author":"Ikramuddin","year":"2009","journal-title":"Am J Manag Care"},{"key":"2022031300300435100_B133","doi-asserted-by":"crossref","first-page":"567","DOI":"10.2337\/dc08-1749","article-title":"Cost-effectiveness of surgically induced weight loss for the management of type 2 diabetes: modeled lifetime analysis","volume":"32","author":"Keating","year":"2009","journal-title":"Diabetes Care"},{"key":"2022031300300435100_B134","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.2337\/dc10-0554","article-title":"Cost-effectiveness of bariatric surgery for severely obese adults with diabetes","volume":"33","author":"Hoerger","year":"2010","journal-title":"Diabetes Care"},{"key":"2022031300300435100_B135","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1463-1326.2012.01692.x","article-title":"Evaluating the cost-effectiveness of laparoscopic adjustable gastric banding versus standard medical management in obese patients with type 2 diabetes in the UK","volume":"15","author":"Pollock","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"2022031300300435100_B136","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1007\/s11695-014-1567-5","article-title":"Bariatric surgery can lead to net cost savings to health care systems: results from a comprehensive European decision analytic model","volume":"25","author":"Borisenko","year":"2015","journal-title":"Obes Surg"},{"key":"2022031300300435100_B137","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/j.soard.2016.12.016","article-title":"Cost-utility analysis for bariatric surgery compared with usual care for the treatment of obesity in Australia","volume":"13","author":"James","year":"2017","journal-title":"Surg Obes Relat Dis"},{"key":"2022031300300435100_B138","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.jdiacomp.2017.04.009","article-title":"Cost-effectiveness of gastric band surgery for overweight but not obese adults with type 2 diabetes in the U.S","volume":"31","author":"Wentworth","year":"2017","journal-title":"J Diabetes Complications"},{"key":"2022031300300435100_B139","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2337\/diacare.29.02.06.dc05-1572","article-title":"Cost-effectiveness and net benefit of enhanced treatment of depression for older adults with diabetes and depression","volume":"29","author":"Katon","year":"2006","journal-title":"Diabetes Care"},{"key":"2022031300300435100_B140","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/j.amepre.2016.01.010","article-title":"Cost-effectiveness evaluation of collaborative care for diabetes and depression in primary care","volume":"51","author":"Johnson","year":"2016","journal-title":"Am J Prev Med"},{"key":"2022031300300435100_B141","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12913-017-2003-z","article-title":"The cost-effectiveness of changes to the care pathway used to identify depression and provide treatment amongst people with diabetes in England: a model-based economic evaluation","volume":"17","author":"Kearns","year":"2017","journal-title":"BMC Health Serv Res"},{"key":"2022031300300435100_B142","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.2337\/dc13-2539","article-title":"Clinical outcomes and cost-effectiveness of continuous positive airway pressure to manage obstructive sleep apnea in patients with type 2 diabetes in the U.K","volume":"37","author":"Guest","year":"2014","journal-title":"Diabetes Care"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/43\/7\/1557\/630574\/dci200017.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/43\/7\/1557\/630574\/dci200017.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T01:28:19Z","timestamp":1723080499000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/43\/7\/1557\/35595\/Cost-effectiveness-of-Interventions-to-Manage"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,11]]},"references-count":142,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,6,11]]},"published-print":{"date-parts":[[2020,7,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dci20-0017","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,11]]}}}